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Abstract
Introduction Obestatin is a controversial gastrointestinal
peptide purported to have metabolic actions.
Objectives This study investigated whether treatment with
a stable obestatin analogue (PEG-OB(Cys10, Cys13))
changed plasma metabolite levels firstly in lean and sub-
sequently in diet-induced obesity (DIO) C57BL6/J mice.
Methods Untargeted LC-HRMS metabolomics experi-
ments were carried out in ESI ? mode with plasma
extracts from both groups of animals. Data were nor-
malised, multivariate and univariate statistical analysis
performed and metabolites of interest putatively identified.
Results In lean mice, 39 metabolites were significantly
changed by obestatin treatment and the majority of these
were increased, including various C16 and C18 moieties of
phosphatidylcholine, phosphatidylethanolamine, phos-
phatidylserine and monoacylglycerol, along with vitamin
A, vitamin D3, tyrosine, acetylcarnitine and 2a-(hydrox-
ymethyl)-5a-androstane-3b,17b-diol. Decreased
concentrations of glycolithocholic acid, 3-dehydroteast-
erone and various phospholipids were observed. In DIO
mice, 25 metabolites were significantly affected and
strikingly, the magnitudes of changes here were generally
much greater in DIO mice than in lean mice, and in con-
trast, the majority of metabolite changes were decreases.
Four metabolites affected in both groups included glycol-
ithocholic acid, and three different long-chain (C18)
phospholipid molecules (phosphatidylethanolamine, plate-
let activating factor (PAF), and monoacylglycerol).
Metabolites exclusively affected in DIO mice included
various phosphatidylcholines, lysophosphatidylcholines
and fatty acyls, as well as creatine and oxidised
glutathione.
Conclusion This investigation demonstrates that obestatin
treatment affects phospholipid turnover and influences
lipid homeostasis, whilst providing convincing evidence
that obestatin may be acting to ameliorate diet-induced
impairments in lipid metabolism, and it may influence
steroid, bile acid, PAF and glutathione metabolism.
Keywords Obestatin  Nutrition  Obesity  Diabetes 
UPLC–MS  Metabolomics
1 Introduction
Obestatin is a metabolic hormone recently discovered in rat
stomach and initially described to inhibit food intake,
decrease intestinal motility and curb body weight gain via
the GPR39 G-protein coupled receptor. Its name is derived
from two Latin words ‘‘obedere’’ meaning to devour and
‘‘statin’’ meaning to suppress. This 23 amino acid peptide
hormone was originally thought to be a direct opponent of
ghrelin, a peptide well characterised as an orexigenic
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hormone which negatively impacts glucose homeostasis;
indeed, both obestatin and ghrelin are produced from post-
translational modification of the same preproghrelin pep-
tide encoded from the ghrelin gene (Dezaki 2013; Zhang
et al. 2005). Primarily produced in the stomach, obestatin is
also expressed in pancreatic and adipose tissue, skeletal
muscle, liver, lung, thyroid, mammary glands and testes,
suggesting it may be multifaceted in its functions and play
autocrine/paracrine roles (Gesmundo et al. 2013; Seim
et al. 2011). It has been found to act both centrally and
peripherally with documented central effects most often
relating to influence on food intake. The peptide has also
been shown to inhibit thirst, regulate sleep patterns, and to
influence anxiety levels and memory function actions
which are thought to occur via stimulation of the vagal
afferent pathway (Ataka et al. 2008; Carlini et al. 2007;
Samson et al. 2007; Szentirmai and Krueger 2006).
Peripheral effects have frequently been reported in the
pancreas and adipose tissue, with additional actions also
documented in the cardiovascular system and skeletal
muscle (Agnew et al. 2012; Trovato et al. 2014).
Among the many gut hormones, obestatin is particularly
controversial due to a lack of experimental reproducibility
in its reported actions, which may in part be attributed to its
short biological half-life in vivo (Vergote et al. 2008). Thus
far, effects of obestatin on feeding behaviour, body weight
and gastrointestinal activity have both been confirmed and
refuted in numerous studies. Furthermore, any interaction
with the GPR39 receptor has been refuted to the extent that
obestatin is now widely considered to be an orphan ligand.
Nevertheless, there is growing interest in obestatin’s
apparent actions on glucose and lipid metabolism (Gar-
gantini et al. 2013) as well as its ability to promote pro-
liferation and to inhibit apoptosis in pancreatic b-cells and
adipocytes (Granata et al. 2008; Tang et al. 2014). For
example, there is evidence that obestatin modulates the
expression of adipogenic and glucoregulatory genes and
that it modulates insulin secretion, adipocyte GLUT-4
translocation, free fatty acid uptake, and glucose uptake
and may inhibit lipolysis in white adipose tissue (Favaro
et al. 2012; Granata et al. 2008, 2012; Tang et al. 2014).
Although some findings are contradictory (Pruszynska-
Oszmalek et al. 2013; Ren et al. 2013), it is becoming clear
that plasma obestatin levels are disturbed following the
development of obesity and diabetes (Seim et al. 2011;
Trovato et al. 2014). Indeed, a growing body of evidence
suggests that obestatin could play a positive role in obesity
and obesity-induced diabetes.
Metabolomics is a systems biology technique used to
investigate changes in the abundance of low molecular
weight metabolites in tissues and biofluids and has been
used to interrogate the mechanisms underlying many dis-
eases and therapies (Bain et al. 2009). Indeed, a number of
targeted and untargeted metabolomics studies have been
conducted to examine the effect of obesity/diabetes on the
metabolome, as well as the influence of clinically approved
anti-diabetic therapies (Bao et al. 2009; Duggan et al. 2011;
Park et al. 2015). This has provided new insights into the
aetiology of obesity and diabetes and has pinpointed
specific disturbances in amino acid, lipid, carbohydrate and
nucleotide metabolism (Park et al. 2015).
Here, we examined the effects of obestatin treatment on
the plasma metabolome. Our first aim was to assess the
controversial status of obestatin as a hormone by estab-
lishing if 6 weeks of daily treatment affects metabolite
levels (thereby indicating if there are modulatory effects on
metabolism) in normal mice. Once this was verified the
second aim was to then determine whether the observed
obestatin-mediated effects on metabolism were substan-
tially different in mice subjected to diet-induced obesity
(DIO). Since the reported actions of obestatin are extre-
mely diverse, potentially with more actions remaining
undiscovered, this investigation focused on peripheral
blood metabolites and employed an untargeted UPLC-MS
metabolomics methodology. Importantly, since obestatin is
physiologically degraded the treatment involved the use of
a novel stable obestatin analogue resistant to degradation.
2 Materials and methods
2.1 Animals and sampling
C57BL6/J male mice were bred in-house, maintained under
constant climatic conditions at 21 C with 12:12 h light–
dark cycles, housed either individually or in pairs and
given free access to food and water. All experiments were
performed in accordance with the Guidance on the Oper-
ation of the Animals (Scientific Procedures) Act, 1986 and
approved by the Queen’s University Belfast Animal Wel-
fare and Ethical Review Body. Lean mice (n = 12)
received a standard laboratory diet, composed of 16.4 %
protein, 4.0 % fat and 48.5 % carbohydrate (3.0 kcal/g;
Teklad global rodent diet, Envigo, UK) for 23 weeks from
birth. For the final 6 weeks animals were injected with
either saline (n = 6) or a modified obestatin peptide
N-PEGylated(Cys10, Cys13)obestatin (n = 6; PEG-OB(Cys10,
Cys13)) (GL Biochem, China) at 50 nmol/kg/day. Injections
were administered subcutaneously in the back of the neck at a
volume of 10 ml/kg and the final weight range of the animals
in each group was 25–33 g (saline) and 26–33 g (PEG-
OB(Cys10, Cys13)).
In a separate experiment the effects of PEG-OB(Cys10,
Cys13) were investigated in DIO mice (n = 11) which
received a standard laboratory diet until 4 weeks of age,
thereafter they received a high fat diet (20.5 % protein,
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36.0 % fat and 35.7 % carbohydrate (5.49 kcal/g; Mouse
Diet, 60 % Fat Calories, BioServ, USA) for 19 weeks. For
the final 6 weeks, mice were separated into two groups and
injected with either saline (n = 5) or PEG-OB(Cys10,
Cys13) (n = 6) at 50 nmol/kg/day as for lean mice. The
final weight range of the DIO animals in each group was
39–55 g (saline) and 42–56 g (PEG-OB(Cys10, Cys13)). At
the end of the 23 week period, mice were fasted for 5 h and
sacrificed by CO2 asphyxiation 3 h after the onset of the
light cycle and exactly 1 h after injection on the final day
of treatment. Blood obtained by cardiac puncture was
collected into pre-chilled heparinised tubes, centrifuged at
30009g for 10 min (4 C) and the resulting plasma
transferred to W/PTFE lined vials (Supelco, USA) prior to
storage at -20 C for metabolomic analysis.
2.2 Sample preparation
Frozen plasma aliquots were thawed on ice and 100 ll was
added to 300 ll of ice cold methanol (100 %) in a 2 ml
sterile Eppendorf tube. Samples were mixed for 30 s and
the protein removed by centrifugation at 13,0009g for
15 min (4 C). Supernatants were evaporated to dryness,
reconstituted in 100 ll of ultra-pure water (Millipore) and
filtered by centrifugation using a 0.22 lm Costar spin-X
centrifuge tube filter (80009g at 4 C for 5 min; Corning
Incorporated, Corning, NY 14831, USA).
2.3 UPLC-MS analysis
All solvents were purchased from Fisher Scientific (Pitts-
burg, USA) and were LC-MS grade or equivalent. Chro-
matography was performed on a Dionex Ultimate 3000
UHPLC system (Dionex, Softron GmbH, Germany) cou-
pled to an LTQ Orbitrap Elite mass spectrometer (Thermo
Fisher Scientific, Bremen, Germany). 5 ll of extracted
plasma was injected (n = 3 injections for each sample)
onto an Acquity UPLC CSH C18 column (2.1 9 100 mm,
1.7 lm, Waters, Wexford, Ireland) operating at 50 C and
applying a binary mobile phase system. The sample man-
ager temperature was maintained at 4 C and the order in
which the samples were injected was randomised
throughout the experiment. The gradient elution buffers
were A (water with 0.1 % formic acid (vol/vol)) and B
(methanol with 0.1 % formic acid (vol/vol)). Solvent B
was varied as follows: 0 min 1 %, 2.5 min 1 %, 16 min
99 %, 18 min 99 %, 18.1 min 1 % and 20 min 1 % with a
flow rate of 0.4 ml min-1. Positive ionisation mode was
employed with these conditions; source heater temperature
at 400 C, sheath gas at 60 (AU), aux gas at 45 (AU) and
sweep gas at 1 (AU), capillary temp was maintained at
325 C and source voltage at 3.5 kV. Mass spectra data
were acquired in profile mode over the 50–1200 m/z range
with a mass resolution of 60,000 at mass 400 (FWHM) and
a scan time of 0.5 s. In further experiments, the samples
were subjected to mass fragmentation analysis (FT HCD
(10, 30 and 70 NCE), MS2) with an isolation width of 1 Da
and 60,000 FWHM at 400 m/z.
Initially the mass spectrometer was calibrated using
LTQ Velos ESI Positive Ion Calibration Solution (Thermo
Scientific) and a mixture of metabolites (100 lg/ml uri-
dine, nicotinic acid, tryptophan, hippuric acid and pheny-
lalanine; ACROS organics) in water. Prior to sample
analysis 10 pooled conditioning samples were injected. To
determine chromatographic reproducibility of retention
times and peak intensities, pooled samples were injected
after every 10 sample injections throughout the experiment
(Graham et al. 2013; Want et al. 2010). These pooled
samples comprised of plasma from this study and a sepa-
rate similar sized pharmacological study (C57BL6/J male
mice).
2.4 Data analysis
UPLC-MS acquired data were analysed using Progenesis
QI software (Waters Corporation, Milford, MA) for peak
alignment, peak picking and data normalisation. A peak
threshold filter of 2.5 AU was applied and peak picking
thresholds were set between 0.5 and 20 min. Data were
normalised to all compounds by correcting for multiple
features to determine a global scaling factor. An output
table was subsequently generated to include paired m/z
retention times and raw and normalised peak intensities for
pools and individual samples. These metabolic features
were exported to Simca P v.14 (Umetrics, Umea, Sweden)
for multivariate analysis by principal component analysis
(PCA) and data quality was assessed via visualisation of
clustering of pools and sample replicates. PCA observa-
tions were indicative of good platform stability (Supple-
mentary Figure 1). UPLC-MS acquired data for all samples
(lean and DIO) were subsequently reanalysed using Pro-
genesis QI as previously described.
On the basis of normalised peak intensities, metabolic
features were reduced by exclusion of those observations
showing no change in magnitude (fold change = 1) and no
significant statistical difference (P[ 0.05, students t test).
Metabolic features were reduced from 3819 to 736 and
3819 to 615 when PEG-OB(Cys10, Cys13) and saline
treated mice were compared within lean and DIO groups,
respectively. This was carried out to avoid over-fitting and
to improve the model’s predictive ability. Using the aver-
age value for each biological replicate the filtered meta-
bolic features were exported to Simca 14 Simca P v.14
(Umetrics, Umea, Sweden) for multivariate analysis. Data
were mean centred, pareto scaled and grouped into PEG-
OB(Cys10, Cys13) and saline treated groups for analysis
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using PCA and orthogonal projection to latent structures
via partial least squares discriminant analysis (OPLS-DA).
The S-plots were used to highlight the ions with the
greatest influence on the separation between PEG-
OB(Cys10, Cys13) and saline treated animals.
Overall model performance was assessed by R2
indicative of variation described by all components in the
model and by Q2, measuring the models ability to predict
class membership. The latter is made possible by the sev-
enfold cross validation default method of the SIMCA
software whereby 1/7th of the data from the model is
omitted and then predicted for class membership. Further
to this, in each case a predictive model was built with the
original data from 2/3 of the animals (training set) and used
to blindly predict the remaining 1/3 (test set). Overall, the
test set observations were assigned to the correct group in
87.5 % of cases. Permutation testing (n = 999) was also
carried out to determine if the models were accurate i.e. the
model fits the training set well and predicts Y accurately
for new observations (Graham et al. 2016).
Discriminatory metabolites as highlighted in the S plot
were investigated by using exact mass when searching
HMDB (Wishart et al. 2009, 2013; Wishart et al. 2007)
(http://www.hmdb.ca/) and the Metlin library (https://
metlin.scripps.edu/) online databases. Putative identifica-
tions were further examined to increase confidence in
identification by mass fragmentation analyses whereby ms/
ms spectra were used to search spectral libraries via addi-
tional online databases m/z cloud (https://www.mzcloud.
org/; http://www.highchem.com/) and MetFrag (http://
msbi.ipb-halle.de/MetFrag/).
3 Results
3.1 Multivariate analysis
Figure 1 displays the PCA analysis of the raw mass spec-
tral data acquired from PEG-OB(Cys10, Cys13) and saline
treated plasma extracts using selected ion features
(P\ 0.05 and fold change = 1). Figure 1a displays the
PCA scores plot for lean mice and Fig. 1b displays the
PCA scores plot for DIO mice. Both scores plots represent
each group treated daily with PEG-OB(Cys10,Cys13) (tri-
angles) or with saline (circles) for a period of 6 weeks. The
PCA scores plots show subtle to moderate separation
between respective classes. Subsequently OPLS-DA was
used to build predictive models capable of discriminating
between PEG-OB(Cys10, Cys13) (triangles) and saline
(circles) treated animals (n = 3 replicates per sample) with
increased power. Figure 2a and 2b display the OPLS-DA
scores plots for PEG-OB(Cys10, Cys13) and saline treated
animals in both lean and DIO groups, respectively. The
scores plot for each model demonstrates clear separation
between the two groups. R2 and Q2 values reflecting the
goodness of fit and the predictive abilities of the models
were 0.879 and 0.123 (1 orthogonal and 2 latent compo-
nents) for the comparison in lean animals and 0.986 and
0.673 (1 orthogonal and 3 latent components) for the
comparison in DIO animals, respectively. These values
signify minimal model variance for both groups, and low to
moderate predictive ability for lean and DIO groups
respectively. These observations are further highlighted in
Fig. 2c and 2d where the permutation plots (n = 999) of
the OPLS-DA models are displayed for both sets of data
respectively.
S-plots as demonstrated by Fig. 3a and b were generated
to identify the metabolites contributing to the discrimina-
tion between PEG-OB(Cys10, Cys13) and saline treated
animals for both lean and DIO groups respectively.
Metabolites with both higher and lower values for pcorr
and p(corr) (1) were those increased and decreased with
PEG-OB(Cys10, Cys13) treatment respectively. These were
the most significant for differentiating between PEG-
OB(Cys10, Cys13) and saline treated animals and are
highlighted by circling on the s-plots. Note, that some ions
with high pcorr and p(corr) (1) values are not highlighted
on the s-plots. These ions had large changes in magnitude
when comparing PEG-OB(Cys10, Cys13) and saline treated
groups but were not significantly different due to the
presence of clear outliers.
Multivariate analysis of technical replicates reported as
Supplementary Figures 2 and 3 produced PCA and OPLS-
DA scores plots for both data sets which showed good
clustering of samples. Furthermore these data mirrored the
scores plots acquired using the averaged biological repli-
cates. The models produced using the larger technical
replicate data set had greater R2, Q2 and better permutation
results using the same ions of interest. These observations
confirm the validity of the original model using biological
replicates for ion selection and furthermore verify that
using a larger sample size would produce better predictive
models.
3.2 Metabolite profile changes with PEG-OB(Cys10,
Cys13) obestatin treatment
Of the original n = 3819 metabolic features, 39 and 25
were tentatively assigned from comparison of PEG-
OB(Cys10, Cys13) and saline treated animals in lean and
DIO groups, respectively (Tables 1, 2). Data presented for
each metabolic feature in Tables 1 and 2 include putative
identifications, mass to charge ratio and retention time,
empirical formula, adduct, deviation from exact mass,
significance value, false discovery rate, percentage
increase, and area under the curve (ROC analysis) values.
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Fig. 1 PCA scores plot displaying the separation for lean mice
(a) and DIO mice (b) treated daily with PEG-OB(Cys10,Cys13)
(triangles) or with saline (circles) for 6 weeks. Explained variances
(R2) were 0.922 and 0.772 and predictive abilities (Q2) were 0.322
and 0.287 for lean and DIO mice respectively
Fig. 2 OPLS-DA scores plot displaying the separation for lean mice
(a) and DIO mice (b) treated daily with PEG-OB(Cys10, Cys13)
(triangles) or with saline (circles) for 6 weeks. Explained variances
(R2) were 0.879 and 0.986 and predictive abilities (Q2) were 0.123
and 0.673 for lean and DIO mice respectively. Corresponding
validation plots for lean mice (c) and DIO mice (d) displaying 999
permutation tests for model built from PEG-OB(Cys10, Cys13) treated
animals
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Among the documented putatively identifiedmetabolites, 29
were significantly increased (Table 1a) and 10 significantly
decreased (Table 1b) with PEG-OB(Cys10, Cys13) treatment
in leanmice, whilst 7were significantly increased (Table 2a)
and 18 were significantly decreased (Table 2b) in DIOmice.
All of these metabolites also remained significantly altered
after P value adjustment by false discovery rate (FDR), and
furthermore, area under the curve values for all metabolites
by ROC analysis were[0.6.
Across both groups, 3 metabolite identifications were
assigned based on fragmentation pattern match with high
resolution spectral library (m/z cloud) (available as online
resources 4–6), and 40 metabolite identifications were
putatively assigned based on in silico fragmentation match.
Among those assigned, four were detected as altered
between PEG-OB(Cys10, Cys13) and saline treated animals
in both lean and DIO groups. Of these, two phospholipids
(PE(18:1(9Z)/0:0) and PAF C-18), and a secondary bile
acid (glycolithocholic acid) were decreased with treatment
in both groups. A monoacylglycerol (MG(18:1(9Z)/0:0/
0:0)) was also increased in lean mice and decreased in DIO
mice (Fig. 4). When comparing PEG-OB(Cys10, Cys13)
and saline treated lean mice, further metabolites were
found to be present at increased levels and these comprised
phospholipids (phosphatidylcholines (PC’s), a lysophos-
phatidylcholine (LysoPC), phosphatidylethanolamines
(PE’s), and phosphatidylserines(PS’s)), monoacylglyc-
erols, polyunsaturated fatty acids (a linolenic acid,
arachidonic acid and metabolite) and vitamins (A, D and D
derivatives). Moreover, tyrosine, acetylcarnitine and 2a-
(hydroxymethyl)-5a-androstane-3b,17b-diol were also
found to be elevated along with three unidentified features.
Additional metabolites found to be at lower levels in lean
mice were phospholipids (PC’s, PE’s, lysoPC’s and a
lysoPE), 3-dehydroteasterone and one unidentified feature.
PEG-OB(Cys10, Cys13) treated DIO animals showed
increased levels of creatine, oxidised glutathione and five
unidentified features when compared to saline treated
controls. Conversely we identified more metabolites at
lower levels in DIO treated animals. These consisted of
phospholipids (PC’s, PE’s, lysoPC’s and lysoPE’s), as well
as 1,7,10,13,16-docosatetraenoic acid, 1-(O-alpha-D-glu-
copyranosyl)-29-keto-(1,3R,31R)-dotriacontanetriol, N-
oleoyl threonine, another metabolite of lipid class (a fatty
acid, fatty acid ester, fatty alcohol or steroid ester by exact
mass search in metlin/hmdb databases) and seven uniden-
tified features (Fig. 5).
4 Discussion
A variety of previous studies have provided evidence
suggesting that obestatin has effects on metabolism. Whilst
many have focused on effects on food intake and body
weight, actions on glucose and lipid metabolism have also
been investigated both under normal physiological condi-
tions and in experimental models of obesity or diabetes
(Agnew et al. 2011; Egido et al. 2009; Granata et al.
2008, 2010, 2012; Green et al. 2007; Nagaraj et al. 2014).
In order to build on these data and to provide a detailed
assessment of the metabolic actions of obestatin, the cur-
rent study employed untargeted metabolomic analysis to
assess whether obestatin influences the levels of circulating
small molecule metabolites. In lean mice, treatment with
the obestatin analogue was found to significantly affect 39
different metabolites, a finding which served as the basis
for a follow-on investigation in DIO mice to understand if
this peptide’s activity was dependent upon nutritional sta-
tus. Importantly, the experimental protocol adopted for
these lean and DIO studies was identical with the exception
Fig. 3 S-Plot displaying ions of interest (circled) for lean (a) and
DIO (b) mice. Ions of interest were selected from 736 and 615 of the
original 3819 metabolic features for lean and DIO mice respectively.
These 736 and 615 ions demonstrated differences in magnitude (fold
change = 1) and significance (P\ 0.05) between PEG-OB(Cys10,
Cys13) and saline treated animals
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that DIO mice received a high fat (HF) diet for 13 weeks
before commencing obestatin treatment at which time they
displayed a mean bodyweight of 46 % higher than lean
mice. To our knowledge, this is the first metabolomic
investigation focussing on the actions of obestatin.
Importantly, we employed a peptide analogue of obestatin
(PEG-OB(Cys10, Cys13)) which demonstrates enhanced
stability and preserved biological activity (Burch et al.
2015; Cowan et al. 2015). The results clearly show that
obestatin treatment alters metabolite profiles in both lean
and DIO mice. OPLS-DA analysis demonstrated clear
separation of mice treated with PEG-OB(Cys10,Cys13)
from saline controls (Fig. 2a, b) and this led to the short-
listing and identification of metabolite ions which were
significantly altered (Tables 1, 2). It was immediately
evident that lean and DIO mice responded differently to
obestatin treatment. Of the 39 and 25 metabolites signifi-
cantly modulated in lean and DIO mice, respectively, there
were only 4 which were commonly affected in both groups.
Of particular note, the majority of affected metabolites
were increased in lean mice, whilst in contrast in DIO mice
the majority of metabolite changes were decreased. Fur-
thermore, regardless of whether metabolites were increased
or decreased the overall magnitude of the responses was
clearly greater in DIO mice (B978 %) compared with lean
mice (B298 %). Interestingly, a large proportion of
metabolites altered in DIO mice could not be putatively
identified potentially suggesting the involvement of lesser
known or uncharacterised biochemical pathways.
The four metabolites commonly affected in both lean
and DIO mice included a phosphatidylethanolamine moi-
ety (PE(18:1(9Z)/0:0)), a platelet activating factor (PAF
C-18), a monoacylglycerol (MG(18:1(9Z)/0:0/0:0)) and a
secondary bile acid (glycolithocholic acid). This clearly
demonstrates a role for obestatin in lipid metabolism and
suggests that some actions may be independent of nutri-
tional status. These 4 metabolites were all significantly
decreased in DIO mice (12–29 %) by PEG-OB(Cys10,
Cys13) treatment, whilst in lean mice three were also
decreased although one (MG(18:1(9Z)/0:0/0:0)) was ele-
vated. Three of the above metabolites are biochemically
similar to one another all being phospholipid molecules
with a single 18 carbon chain. Interestingly, long chain
phospholipids are negatively associated with obesity and
diabetes and PAF is an inflammatory mediator which acts
in part to promote cytokine production (Giesbertz et al.
2015; Li and Mitra 1996; Menezes-Garcia et al. 2014).
Indeed, PAF receptor deficient mice fed a high carbohy-
drate diet have been shown to display reduced adipose
tissue inflammation and improved glucose homeostasis
(Menezes-Garcia et al. 2014), whilst other studies have
reported increases in bile acid levels with HF feeding for
relatively short periods (Sayin et al. 2013; Sun et al. 2015).T
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Therefore, a key function of obestatin may be to control
inflammation and to preserve healthy lipid and cholesterol
metabolism both under normal physiological circumstances
and also under situations of DIO/diabetes, and such actions
could be mediated via the observed reductions in these
particular metabolites. In support of this suggestion,
obestatin has been shown to reduce obesity-induced
increases in inflammatory cytokines, to decrease insulin
sensitivity and to decrease triglyceride levels. Furthermore,
it has also been shown to decrease the expression of
cholesterol transporter ATP-binding cassette A1 (ABCA1)
in bovine white adipose tissue (A. Agnew et al. 2011; Grala
et al. 2010; Granata et al. 2012; Hotamisligil 2006).
Notably, the majority of circulating metabolites affected
by PEG-OB(Cys10,Cys13) treatment in lean mice were
phospholipids. Most of these were increased and most were
species of PC, LysoPC, PE or PS, although there were also
some instances of decreased PC, LysoPC, PE or LysoPE
phospholipid species. This suggests that obestatin influ-
ences the turnover of phospholipids. Indeed, many plasma
phospholipids originate from lipoproteins (Miller et al.
2011), and therefore obestatin’s ability to regulate phos-
pholipid levels could be linked to its ability to regulate
HDL, LDL and VLDL levels (Catak et al. 2014; Nagaraj
et al. 2008, 2009). Other metabolites which were increased
with PEG-OB(Cys10,Cys13) treatment in lean mice inclu-
ded monoacylglycerols, polyunsaturated fatty acids, vita-
min A and D forms, an amino acid (tyrosine), an
acylcarnitine (acetylcarnitine), a steroid (2a-(hydrox-
ymethyl)-5a-androstane-3b,17b-diol) and some unknown
metabolites. As acylcarnitines facilitate transport of fatty
acids into the mitochondria for b-oxidation, an increase in
acetylcarnitine could reflect decreased mitochondrial util-
isation (Ju¨llig et al. 2007). Obestatin may therefore pro-
mote glucose utilisation over fatty acid utilisation for
energy production when fatty acids are present under
Fig. 4 Box-and-whisker plots show the relative abundance of 4
circulating metabolites which were commonly affected by PEG-
OB(Cys10,Cys13) treatment in lean mice (a–d) and DIO mice (e–h).
Metabolites are a, e PE(18:1(9Z)/0:0), b, f PAF C-18, c,
g MG(18:1(9Z)/0:0/0:0) and d, h glycolithocholic acid. Whiskers
indicate min and max, bottom and top of boxes indicate 25th and 75th
percentiles, and line through centre of each box and ‘?’ within box
represent median and mean, respectively. P values were calculated by
the Student’s t test with ***P\ 0.001; **P\ 0.01 and *P\ 0.05
indicating significant differences between PEG-OB(Cys10,Cys13)
treatment and saline
PE(18:1(9Z)/0:0) 
PAF C-18 
MG(18:1(9Z)/0:0/0:0) 
Glycolithocholic acid  
LysoPC, LysoPE
7,10,13,16-Docosatetraenoic acid
Fay acyls   
Creane, Oxidised glutathione 
Unknowns 
PC’s, LysoPC’s, PE’s, LysoPE & PS’s 
MG(0:0/16:0/0:0)
Vitamins 
Polyunsaturated fay acids
20-Hydroxyeicosatetraenoic acid
Tyrosine , Acetylcarnine
2α-(Hydroxymethyl)-5α-androstane-3β,17β-diol
3-Dehydroteasterone
Unknowns 
DIO Mice  Fig. 5 Venn diagram shows
metabolites/metabolite classes
increased and/or decreased in
lean and DIO mice treated with
PEG-OB(Cys10,Cys13).
Directions of change are
represented by opened and
closed arrows for lean and DIO
animals respectively
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normal physiological conditions. This assertion is based on
the observed increases in the circulating levels of polyun-
saturated fatty acids and monoacylglycerols in PEG-
OB(Cys10,Cys13) treated animals. It may even reflect a
tendency for obestatin to safeguard against potential
hyperglycaemia. Interestingly, physiological levels of
polyunsaturated fatty acids have been associated with
decreased and increased proinflammatory and anti-inflam-
matory markers, respectively (Ferrucci et al. 2006).
Therefore, slightly elevated levels observed in lean mice
treated with PEG-OB(Cys10, Cys13) further corroborate a
role for obestatin in limiting inflammation. In addition, the
observed increases in 2a-(hydroxymethyl)-5a-androstane-
3b,17b-diol, vitamin D3 and vitamin A metabolites could
also be viewed as beneficial. 2a-(hydroxymethyl)-5a-an-
drostane-3b,17b-diol is a metabolite of dehydroepiandros-
terone (DHEA) and dihydrotestosterone (DHT) and both
insulin resistance and obesity have been associated with
low androgen and vitamin D levels (Navarro et al. 2015;
Pereira-Santos et al. 2015). Furthermore, vitamin A is
known to improve insulin sensitivity and has been sug-
gested essential for maintenance of pancreatic b-cell
function and mass (Jeyakumar et al. 2011; Trasino et al.
2015).
Numerous studies have associated increased levels of
the amino acid tyrosine with diabetes and obesity, although
a few have reported decreased levels in this setting (Mi-
halik et al. 2012; Tranchida et al. 2015; X. Zhang et al.
2009). Furthermore, 3-dehydroteasterone is a sterol lipid of
dietary source and a decreased level of this metabolite with
PEG-OB(Cys10,Cys13) treatment in animals maintained on
the same diet suggests that obestatin may inhibit its uptake
from the gut.
Of the seven metabolites increased with PEG-
OB(Cys10,Cys13) treatment in DIO mice only two could be
putatively identified: creatine and oxidised glutathione
(GSSG). GSSG is the oxidised form of the antioxidant
reduced glutathione (GSH), and increased GSSG andGSSG/
GSH ratio are considered to be indicative of oxidative stress
and are associated with obesity and diabetes (Savini et al.
2013). However, it is not clear what effect PEG-OB(Cys10,
Cys13) treatment has on the glutathione system, when the
observed increase in GSSGmay also be explained by sample
storage conditions. Indeed, GSH is known to degrade at a
much faster rate than GSSG, and is also susceptible to
autoxidation (Lin et al. 2006); therefore, GSSG measured
here may not reflect true plasma GSSG levels.
Increased plasma creatine could suggest decreased cre-
atine uptake by skeletal muscle, and interestingly, skeletal
muscle absorption of creatine is believed to be promoted by
insulin (Steenge et al. 1998). The increased creatine levels
observed here may thus reflect decreased insulin produc-
tion with PEG-OB(Cys10, Cys13) treatment. Furthermore,
hyperinsulinemia is one of the hallmarks of insulin resis-
tance and thus obestatin could play a protective role against
the development of insulin resistance. Indeed, supportive
evidence for this suggestion is provided by a report that
creatine levels decrease whilst glucose and insulin levels
increase in HF fed mice (Duggan et al. 2011).
In addition to those already discussed, further metabo-
lites found to decrease with PEG-OB(Cys10, Cys13) treat-
ment in DIO mice included polyunsaturated fatty acids and
fatty acyls. Significantly increased levels of fatty acids are
well documented in obesity and diabetes, and so reduced
polyunsaturated fatty acids and fatty acyls with PEG-
OB(Cys10, Cys13) treatment in DIO animals suggests that
obestatin has the potential to protect against lipid dysreg-
ulation under these conditions (Lopaschuk et al. 2010).
Such protective effects of obestatin could involve
decreasing adipose tissue lipolysis (Granata et al. 2012)
and/or increasing fatty acid clearance by b-oxidation.
Altered levels of plasma lipoproteins (the source of
phospholipids) in plasma are linked to inflammation, b-cell
dysfunction, obesity and diabetes (Anderson et al. 2014;
Miller et al. 2011; Roehrich et al. 2003). LysoPC’s are major
components of oxidized low density lipoproteins (Ox-LDL),
and not surprisingly increased levels have been correlated
with endothelial dysfunction and atherogenesis, as well as
inflammation and oxidative stress (Aiyar et al. 2007; Galili
et al. 2007; Schmitz and Ruebsaamen 2010). Furthermore,
phospholipids have been reported to be susceptible to gly-
coxidation and are suggested to be a potential source of
oxidative damage to tissues (Miyazawa et al. 2008; Podrez
2002). The ability of PEG-OB(Cys10, Cys13) treatment to
reduce high phospholipid levels in plasma of DIO animals
therefore suggests that obestatin may be able to ameliorate
lipoprotein/phospholipid mediated proinflammatory stress
associated with complications of obesity and/or diabetes.
Interestingly, as previously discussed, longer rather than
shorter chain phospholipids have been negatively associ-
ated with obesity and diabetes, and the hypoglycaemic
effect of insulin has been shown to improve when phos-
pholipids of reducing carbon numbers from C18 to C10 are
involved (Giesbertz et al. 2015; Li and Mitra 1996).
Therefore, reduction of phospholipids with carbon lengths
of C18 as observed here in DIO mice treated with PEG-
OB(Cys10, Cys13) suggests that obestatin may be promot-
ing insulin absorption/sensitivity by reducing the ratio of
longer to shorter carbon chain phospholipids.
5 Concluding remarks
In summary, this UPLC-MS metabolomic investigation has
elucidated a number of plasma metabolite changes which
occur as a consequence of obestatin treatment. In lean mice
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39 metabolites were significantly affected, strongly sug-
gesting that obestatin modulates metabolism and thereby
appearing to justify its proposed status as a hormone.
The fact that there were 4 metabolites commonly
affected in DIO and lean mice demonstrates that there is at
least some consistency in their responses to obestatin.
However, there were a further 21 unique metabolite
responses in DIO mice, clearly showing that nutritional
status has a bearing on obestatin’s mode of action. The
metabolite changes observed here suggest that this peptide
influences lipid metabolism and may also play an anti-
inflammatory role. Furthermore, some of the observed
metabolite changes may underlie the previously reported
beneficial actions of obestatin on insulin resistance,
hyperglycaemia and lipid dysregulation. Together, the
findings of this study clearly highlight the potential value
of metabolomics to delineate the metabolic actions of
poorly characterised physiological hormones.
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